Stryker Corporation SYK NYSE

Stryker Corporation (SYK) reported total assets of $47.84B and total liabilities of $25.42B for fiscal year 2025, resulting in total equity of $22.42B.

The company held $4.1B in cash and short-term investments. Total debt stood at $14.86B, with net debt of $10.85B. The Debt-to-Equity (D/E) ratio was 0.66 (moderate).

Current ratio is 1.89, indicating strong short-term liquidity. Interest coverage is 8.1x (strong).

Criteria supported by this page:

• HEALTH (83/100, Pass) — Debt-to-Equity of 0.66, current ratio of 1.89, interest coverage 8.1x — balance sheet is strong
• MOAT (86/100) — Total assets $47.84B and equity $22.42B support the company's competitive scale
• VALUE (32/100) — Debt-to-Equity 0.66 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 74/100 with 5/7 criteria passed.

AMGN

Amgen Inc.

$350.95

+0.32%

ABT

Abbott Laboratories

$101.07

+0.38%

GILD

Gilead Sciences, Inc.

$140.45

+1.02%

PFE

Pfizer Inc.

$27.13

-0.77%

DHR

Danaher Corporation

$198.61

+1.40%

SNY

Sanofi

$47.64

+1.45%

MDT

Medtronic plc

$88.12

+0.14%

VRTX

Vertex Pharmaceuticals Incorporated

$444.28

+0.96%